Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research: Personalized Infectious Disease Medicine for the Most Vulnerable At-Risk Patients

• Published in: PHAGE (Print) Vol. 1; no. 2; pp. 66 - 74
• Main Authors: Terwilliger, Austen L, Gu Liu, Carmen, Green, Sabrina I, Clark, Justin R, Salazar, Keiko C, Hernandez Santos, Haroldo, Heckmann, Emmaline R, Trautner, Barbara W, Ramig, Robert F, Maresso, Anthony W
• Format: Journal Article
• Language: English
• Published: United States Mary Ann Liebert, Inc., publishers 01-06-2020
• Subjects: bacteriophage; BCM tailor labs; phage therapy
• ISSN: 2641-6530; 2641-6549
• DOI: 10.1089/phage.2020.0007

Mutation is the most powerful driver of change for life on Earth. Pathogenic bacteria utilize mutation as a means to survive strong live-die selective pressures generated by chemical antibiotics. As such, the traditional drug-making pipeline, characterized by significant financial and time investment, is insufficient to keep pace with the rapid evolution of bacterial resistance to structurally fixed and chemically unmalleable antibacterial compounds. In contrast, the genetic diversity and adaptive mutability of the bacteriophage can be leveraged to not only overcome resistance but also used for the development of enhanced traits that increase lytic potential and therapeutic efficacy in relevant host microenvironments. This is the fundamental premise behind Baylor College of Medicine's Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR) initiative. In this perspective, we outline the concept, structure, and process behind TAILΦR's attempt to generate a personalized therapeutic phage that addresses the most clinically challenging of bacterial infections.